COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

USCAST INC
SCHENECTADY, NY · EIN 465724726 · Form 990PF · FY2025 · NTEE U99 · Science & Technology · Micro (<$100K) · uscast.org
revenue
$3K
expenses
$12K
net assets
$100K
employees
—
profile · synthesized from sources

USCAST INC is a scientific organization focused on establishing standards for antimicrobial susceptibility testing. It develops interpretive criteria (breakpoints) to guide effective antibiotic use and combat antimicrobial resistance. The organization synthesizes pharmacometric and clinical data to address critical gaps and controversies in breakpoint determination, supporting healthcare providers globally.

named programs · 3 · from sources

What they call their work

Annual Virtual Meeting and Stakeholder Engagement
Hosts virtual meetings and solicits public feedback to inform the development and refinement of susceptibility breakpoints.
Rationale Documents and Position Papers
Produces evidence-based publications and statements to support breakpoint recommendations and advocate for harmonization across international standards organizations.
USCAST STIC Tables
Develops and publishes annually updated in vitro susceptibility test interpretive criteria (STIC) for antibacterial agents, focusing on clinically critical and controversial breakpoints.
activities · 2 groups

What they do

  • Global Tuberculosis Drug Development and Access 5 activities
    • Conducting comparative analyses of antimicrobial breakpoints
      Performs and publishes comparative analyses of susceptible breakpoints across international standards organizations (USA-FDA, CLSI, EUCAST-SC, USCAST) for key drug classes such as fluoroquinolones, aminoglycosides, oxazolidinones, and peptides to inform harmonization and best practices.
    • Disseminating STIC resources through public platforms
      Makes updated susceptibility test interpretive criteria (STIC) tables and supporting materials widely accessible by publishing them online in searchable formats, including video presentations, slide decks, and public document repositories to ensure broad stakeholder access.
    • Establishing standards for antibacterial testing and interpretation
      Develops and establishes scientifically rigorous standards for testing and interpreting the activity of antibacterial agents, in collaboration with global partners, to support antimicrobial stewardship and clinical decision-making.
    • Generating and publishing susceptibility test interpretive criteria (STIC)
      Conducts research to generate, update, and finalize in vitro susceptibility test interpretive criteria (STIC) for various antibiotic-pathogen combinations, including ceftriaxone, azithromycin, piperacillin-tazobactam, and minocycline, using pharmacometric and evidence-based approaches. Publishes annual editions (e.g., 2021, 2024, 2025) as downloadable, searchable PDFs with supporting rationale documents.
    • Publishing specialized rationale and evaluation documents for antimicrobial agents
      Produces and publishes detailed rationale and evaluation documents for specific antimicrobial agents, including oritavancin, tedizolid, dalbavancin, telavancin, aminoglycosides, fluoroquinolones, and polymyxins, with multiple versions released between 2016 and 2019 to support transparent and evidence-based breakpoint decisions.
  • General Operating Support Grants 1 activity
    • Funding general operating support for Ronald McDonald House Charities of Madison
      Awards grants to support the general operations of Ronald McDonald House Charities of Madison, enabling its services for families of hospitalized children.
financials · form 990PF · fy2025
revenue
Total revenue$3K
Contributions & grants——
Program service revenue——
Investment income$3K100%
Other revenue—
expenses
Total expenses$12K
Program expenses—
Admin / overhead—
Fundraising—
Salaries & benefits$0
Grants paid out$0
balance sheet
Total assets$100K
Cash—
Investments—
Liabilities—
Net assets$100K
6 years on record · 2020–2025 · YoY revenue +192.3%
relationships · 9

Who they work with

  • David Andes, MD Partner — Executive Committee Member of USCAST and contributor to oral cephalosporin STIC development
  • E. coli Partner — Pathogen under study for susceptibility testing with oral cephalosporins.
  • Enterobacterales Partner — Pathogen group under study for susceptibility testing with trimethoprim-sulfamethoxazole for uncomplicated urinary tract infections.
  • Grady Health System Partner — Collaborates with Grady Health System in infectious disease research and breakpoint development.
  • Jason M. Pogue, Pharm. D. Partner — Chairman of USCAST and contributor to Trimethoprim-Sulfamethoxazole STIC development
  • Neisseria gonorrhoeae Partner — Pathogen under study for susceptibility testing with ceftriaxone and azithromycin.
  • Ronald McDonald House Charities of Madison Partner — Recipient of general operating support grant
  • S. aureus Partner — Pathogen under study for susceptibility testing with oral cephalosporins.
  • global partners Partner — Collaborates with global partners to establish standards for antibacterial agent testing and interpretation.
strategies · 4

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Community-Driven Evidence Generation
    methodology: community_driven_research_prioritization
    By prioritizing pathogen-drug evaluations based on clinician and community input and focusing on high-impact controversies, USCAST generates targeted evidence that addresses real-world clinical uncertainties, because stakeholder-informed research increases the applicability and adoption of new guidelines.
  • Context-Specific and Harmonized Breakpoint Development
    methodology: context_specific_breakpoint_setting
    By setting susceptibility breakpoints based on specific clinical contexts and standardized regimens, and actively harmonizing them across regions, USCAST ensures test interpretations are clinically relevant and globally consistent, because uniform standards reduce diagnostic discrepancies and improve treatment accuracy.
  • Global Network for Antibiotic Stewardship
    methodology: global_network_for_antibiotic_stewardship
    By integrating scientific research, education, and policy development within a global network, USCAST advances antibiotic stewardship, because coordinated international efforts amplify the impact of evidence-based breakpoint recommendations on clinical practice and public health.
  • Pharmacometric Modeling for Breakpoint Setting
    methodology: pharmacometric_modeling_for_breakpoint_setting
    By using pharmacokinetic/pharmacodynamic (PK/PD) modeling and adjusting for clinical variables like renal function, USCAST develops interpretive breakpoints that better predict clinical outcomes, because these models link in vitro susceptibility to real-world dosing and patient factors.